Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 17/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15013193 | 1.00 | LPAR1 (0.54) | LPAR1LPAR3LPAR2NTRK1ENPP2 | |
| SCHEMBL14710563 | 0.88 | LPAR1 (0.57) | LPAR1LPAR3LPAR2NTRK1 | |
| SCHEMBL15013215 | 0.88 | LPAR1 (0.56) | LPAR1LPAR3LPAR2NTRK1 | |
| SCHEMBL15013213 | 0.88 | LPAR1 (0.56) | LPAR1LPAR3LPAR2NTRK1 | |
| SCHEMBL16211066 | 0.86 | LPAR1 (0.53) | LPAR1LPAR3NTRK1 | |
| SCHEMBL16211067 | 0.86 | LPAR1 (0.53) | LPAR1LPAR3NTRK1 | |
| SCHEMBL15013339 | 0.85 | LPAR1 (0.59) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14790532 | 0.85 | LPAR1 (0.52) | LPAR1LPAR3LPAR2ENPP2 | |
| SCHEMBL15013337 | 0.85 | LPAR1 (0.59) | LPAR1LPAR3LPAR2 | |
| SCHEMBL14790534 | 0.84 | LPAR1 (0.51) | LPAR1LPAR3LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2014-11-06 | — | — | US | claimed |
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329871-A1 | SMALL MOLECULE ANTI-FIBROTIC COMPOUNDS AND USES THEREOF | MMP1, COL1A1, COL2A1 | LPAR1 709/4885LPAR3 699/4885LPAR2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.